Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
Polyrizon Signs Non–Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
Polyrizon Ltd. recently announced it has signed a non-binding Letter of Intent (LOI) with a biotech company focused on psychedelic-derived...SPECIAL FEATURE - Analytical Testing – Diverse Demands & Therapies Require Diverse Analyses
Contributor Cindy H. Dubin highlights how analytical testing has evolved to address diverse pharmaceutical therapeutics in research and development.
MICRONEEDLE MANUFACTURING - The Value of a Manufacturing-Oriented Microneedle Mindset
Andrew Riso says despite the significant buzz surrounding microneedle technology, a considerable gap remains between innovations and market-ready products. While early stage development and preclinical studies have shown promising results, the challenge of translating these advancements into scalable, commercially viable products persists.
NEW PRODUCT INTRODUCTION - Addressing the Pitfalls of Progressing From Pilot to Product Through Effective New Product Introduction
Uwe Hanenberg, PhD, Wolfram Bühler, and Radoslaw Kaczanowski, PhD, explore the risks and challenges pharmaceutical companies face when undertaking NPI to ensure new products successfully reach the market and patients and examine the strategies CDMOs are adopting to ensure the smooth delivery of these projects from discovery to commercialization.
Sanara MedTech Inc. Announces Exclusive License & Distribution Agreement With & Minority Investment in Biomimetic Innovations Ltd
Sanara MedTech Inc. recently announced the execution of an exclusive license and distribution agreement with Biomimetic Innovations Ltd. In tandem,...Inmagene Reports Positive Topline Results of a Nondepleting Anti-OX40 Monoclonal Antibody With an Extended Half-Life for the Treatment of Atopic Dermatitis
Inmagene Biopharmaceuticals reports additional positive topline results from the Phase 2a trial of IMG-007 in patients with moderate-to-severe AD, along...Silo Pharma Awarded Patent for Groundbreaking PTSD Treatment
Silo Pharma, Inc. recently announced the US Patent and Trademark Office (USPTO) issued a Notice of Allowance for patent application...Ikena Oncology & Inmagene Biopharmaceuticals Announce Agreement for Merger & Private Placement
Ikena Oncology, Inc. and Inmagene Biopharmaceuticals recently announced they have entered into a definitive merger agreement. In connection with the...ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative
ABVC BioPharma, Inc. recently announced in response to the discontinuation of Prozac due to increasing concerns around side effects, ABVC...SCYNEXIS Initiates Dosing in Phase 1 Trial of a Second-Generation Fungerp Candidate for Invasive Fungal Infections
SCYNEXIS, Inc. recently announced it has completed the dosing of the first cohort of subjects in its Phase 1 trial...
